Seroprevalence of Immunoglobulin G Antibody among Contacts of COVID-19 Cases: A Study from India
DOI:
https://doi.org/10.31584/jhsmr.2021823Keywords:
contact of cases, family contact, IgG antibody, SARS-CoV2, serosurveillanceAbstract
Objective: To estimate COVID-19 seropositivity among contacts of cases and to compare the seropositivity among different types of contact for assessing the differential risk & transmission dynamics.
Material and Methods: A large-scale population-based serosurvey was carried out among the general population of Ahmedabad during the second half of October 2020. The contacts of cases were selected based on the population proportion and enrolled as an additional category. The seropositivity among the contacts was estimated using the enzyme-linked immunosorbent assay and compared with different types of contact and available demographic factors.
Results: As of October 2020, the seropositivity against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV2) among contacts of cases in Ahmedabad was 26.0% [95% confidence interval 24.2–28.0]. The seropositivity among family contacts was significantly higher (28.8%) compared to other contacts (24.4%) (Z=2.19, p-value=0.028). This trend was seen across all age groups and both sexes. The seropositivity was higher among females (27.7%) compared to males (24.5%) but the difference was statistically not significant (Z=1.64, p-value=0.101). In terms of age groups, the positivity had an increasing trend up to 60 years but declined after that.
Conclusion: A seropositivity of 26.0% among contacts indicates that a large proportion of contacts demonstrated Immunoglobulin-G antibodies. This highlights asymptomatic transmission and/or low sensitivity of the diagnostic tests. The current strategy for contact tracing and testing among contacts is justified based on the significantly higher seropositivity among family contacts.
References
Munster VJ, Koopmans M, Van Doremalen N, Van Riel D, Emmie de Wit. A Novel Coronavirus Emerging in China A Novel Coronavirus Emerging in China-Key Questions for Impact Assessment. N Engl J Med 2020;38:692-4.
Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirusinfected pneumonia. N Engl J Med 2020;382:1199–207.
Lipsitch M, Swerdlow DL, Finelli L. Defining the epidemiology of Covid-19 - studies needed. N Engl J Med 2020;382:1194-6.
GeurtsvanKessel CH, Okba NMA, Igloi Z, Bogers S, Embregts CWE, Laksono BM, et al. An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment. Nat Commun 2020;11:3436.
World Health Organization. Population-based age-stratified seroepidemiological investigation protocol for COVID-19 virus infection. Geneva: WHO; 2020.
Hanage WP, Qiu X, Kennedy-Shaffer L. Snowball sampling study design for serosurveys in the early COVID-19 pandemic. Dash Havard Edu 2020;1-12.
Kumar MS, Bhatnagar T, Manickam P, Kumar VS, Rade K, Shah N, et al. National sero-surveillance to monitor the trend of SARS-CoV-2 infection transmission in India: Protocol for community-based surveillance. Indian J Med Res 2020; 151:419-23.
Xu X, Sun J, Nie S, Li H, Kong Y, Liang M, et al. Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China. Nat Med 2020;26:1193–5.
Murhekar M V, Bhatnagar T, Selvaraju S, Rade K, Saravanakumar V, Wesley Vivian Thangaraj J, et al. Prevalence of SARSCoV- 2 infection in India: findings from the national serosurvey, May-June 2020. Indian J Med Res 2020;152:48–60.
Hou H, Wang T, Zhang B, Luo Y, Mao L, Wang F, et al. Detection of IgM and IgG antibodies in patients with coronavirus disease 2019. Clin Transl Immunology 2020;9:e01136.
World Health Organization. Public health surveillance for COVID-19: interim guidance. Geneva: WHO; 2020.
Indian Council of Medical Research. Press Release ICMR advises States to conduct sero-survey to measure Coronavirus exposure in the population using IgG ELISA Test. New Delhi: Indian Council of Medical Research; 2020.
Sapkal G, Shete-Aich A, Jain R, Yadav PD, Sarkale P, Lakra R, et al. Development of indigenous IgG ELISA for the detection of anti-SARS-CoV-2 IgG. Indian J Med Res 2020;151:444-9.
Chirathaworn C, Sripramote M, Chalongviriyalert P, Jirajariyavej S, Kiatpanabhikul P, Saiyarin J, et al. SARS-CoV-2 RNA shedding in recovered COVID-19 cases and the presence of antibodies against SARS-CoV-2 in recovered COVID-19 cases and close contacts, Thailand, April-June 2020. PLoS One 2020;15: e0236905.
Martinez-Fierro ML, R os-Jasso J, Garza-Veloz I, Reyes-Veyna L, Cerda-Luna RM, Duque-Jara I, et al. The role of close contacts of COVID-19 patients in the SARS-CoV-2 transmission: an emphasis on the percentage of nonevaluated positivity in Mexico. Am J Infect Control 2021;49:15-20.
Havers FP, Reed C, Lim T, Montgomery JM, Klena JD, Hall AJ, et al. Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020. JAMA Intern Med 2020;180:1776–86.
Wang X, Guo X, Xin Q, Pan Y, Hu Y, Li J, et al. Neutralizing Antibodies Responses to SARS-CoV-2 in COVID-19 Inpatients and Convalescent Patients [published online ahead of print, 2020 Jun 4]. Clin Infect Dis 2020. doi: 10.1093/cid/ciaa721.
Hu WT, Howell JC, Ozturk T, Benameur K, Bassit LC, Ramonell R, et al. Antibody Profiles According to Mild or Severe SARSCoV- 2 Infection, Atlanta, Georgia, USA, 2020. Emerg Infect Dis 2020;26:2974-8.
Okba NM, Müller MA, Li W, Wang C, GeurtsvanKessel CH, Corman VM, et al. Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients. Emerg Infect Dis 2020;26:1478-88.
Kellam P, Barclay W. The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection. J Gen Virol 2020;101:791-7.
Cervia C, Nilsson J, Zurbuchen Y, Valaperti A, Schreiner J, Wolfensberger A, et al. Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19. J Allergy Clin Immunol 2021;147:545-57.e9.
Nikolai LA, Meyer CG, Kremsner PG, Velavan TP. Asymptomatic SARS Coronavirus 2 infection: Invisible yet invincible. Int J Infect Dis 2020;100:112-6.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
